12:00 AM
Feb 21, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

ANX-514 regulatory update

Adventrx said FDA indicated an additional clinical trial would be required for approval of cancer candidate ANX-514 following a meeting with the agency. The company said FDA's request...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >